Healthcare Services

Oncolytic Adenovirus Market Outlook 2026–2035: Growth Drivers and Industry Forecast

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oncolytic adenovirus market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Oncolytic Adenovirus Market from 2026 to 2030?

The oncolytic adenovirus market has experienced substantial growth in recent years. It is projected to expand from $132.49 billion in 2025 to $143.57 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. This historical growth can be attributed to several factors, including the development of first-generation adenovirus-based therapies, the increasing prevalence of melanoma and prostate cancer, rising investment in oncolytic virus research, early adoption by cancer research institutes, and growing collaborations between biotech and academic institutions.

The oncolytic adenovirus market is projected to experience substantial expansion over the coming years. This market is forecast to reach $195.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. The anticipated growth during this period is driven by several factors, including the escalating demand for engineered adenovirus treatments, wider use in breast, ovarian, and lung cancer cases, increased involvement from biotechnology firms, greater financial support for clinical trials and research & development, and the enhancement of gene therapy capabilities within hospitals and research institutions. Key trends expected over the forecast horizon involve the growing integration of AI and big data in oncolytic virus investigations, the expanding utilization of genomics and precision medicine in virus engineering, a surge in the deployment of digital platforms for overseeing clinical trials, increasing automation in virus production and quality assurance, and the heightened implementation of IoT-enabled systems for monitoring virus storage and distribution.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Drivers Are Affecting Demand In The Oncolytic Adenovirus Market?

The escalating occurrence of cancer is anticipated to stimulate the future expansion of the oncolytic adenovirus market. Cancer is characterized by unrestrained cell growth and its spread to other body parts. The increasing incidence of cancer is attributed to an aging global population, various lifestyle choices, environmental exposures, genetic predispositions, and advancements in detection methods. Oncolytic adenovirus offers a promising strategy by selectively targeting and eradicating cancer cells to manage the rising cancer rates. For instance, in May 2024, reports from the National Cancer Institute (NCI), a US-based government agency, revealed nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Furthermore, in 2023, data from the Australian Bureau of Statistics, an Australia-based government agency, indicated that 1.8% of Australians had cancer, with males (2.1%) being marginally more affected than females (1.6%), especially those aged 75 and over. Thus, the growing incidence of cancer is a key factor driving growth in the oncolytic adenovirus market.

Which Segments Are Gaining Traction In The Oncolytic Adenovirus Market?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

Which Trends Are Guiding The Evolution Of The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are prioritizing combination therapies, such as VCN-01, which integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to specifically infect and destroy cancer cells, concurrently boosting the effectiveness of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) has awarded Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation is applicable to VCN-01 when utilized in conjunction with gemcitabine and nab-paclitaxel for the management of metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and replicates within tumor cells, assisting in the breakdown of the tumor stroma, which represents a key obstacle to effective cancer treatment.

Who Are The Top-Performing Companies In The Oncolytic Adenovirus Market In Recent Years?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

How Does The Oncolytic Adenovirus Market Perform Across Major Global Regions?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncolytic Adenovirus Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Viral Hepatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Adeno Associated Viral Vectors Market Report 2026

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Viral Inactivation Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795